581 related articles for article (PubMed ID: 16406828)
21. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
22. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis.
Rolo AP; Teodoro JS; Palmeira CM
Free Radic Biol Med; 2012 Jan; 52(1):59-69. PubMed ID: 22064361
[TBL] [Abstract][Full Text] [Related]
23. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.
Nocito A; Dahm F; Jochum W; Jang JH; Georgiev P; Bader M; Renner EL; Clavien PA
Gastroenterology; 2007 Aug; 133(2):608-18. PubMed ID: 17681180
[TBL] [Abstract][Full Text] [Related]
24. A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
Krishnan A; Abdullah TS; Mounajjed T; Hartono S; McConico A; White T; LeBrasseur N; Lanza I; Nair S; Gores G; Charlton M
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G666-G680. PubMed ID: 28232454
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
[TBL] [Abstract][Full Text] [Related]
26. Fatty liver in the intensive care unit.
Paquot N; Delwaide J
Curr Opin Clin Nutr Metab Care; 2005 Mar; 8(2):183-7. PubMed ID: 15716798
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of hepatotoxicity.
Jaeschke H; Gores GJ; Cederbaum AI; Hinson JA; Pessayre D; Lemasters JJ
Toxicol Sci; 2002 Feb; 65(2):166-76. PubMed ID: 11812920
[TBL] [Abstract][Full Text] [Related]
28. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury.
Serviddio G; Bellanti F; Tamborra R; Rollo T; Capitanio N; Romano AD; Sastre J; Vendemiale G; Altomare E
Gut; 2008 Jul; 57(7):957-65. PubMed ID: 18308829
[TBL] [Abstract][Full Text] [Related]
29. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes.
Igoudjil A; Massart J; Begriche K; Descatoire V; Robin MA; Fromenty B
Toxicol In Vitro; 2008 Jun; 22(4):887-98. PubMed ID: 18299183
[TBL] [Abstract][Full Text] [Related]
30. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
31. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial abnormality and oxidative stress in nonalcoholic steatohepatitis.
Kojima H; Sakurai S; Uemura M; Fukui H; Morimoto H; Tamagawa Y
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S61-6. PubMed ID: 17331168
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
34. Role of ceramides in nonalcoholic fatty liver disease.
Pagadala M; Kasumov T; McCullough AJ; Zein NN; Kirwan JP
Trends Endocrinol Metab; 2012 Aug; 23(8):365-71. PubMed ID: 22609053
[TBL] [Abstract][Full Text] [Related]
35. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes.
Berson A; De Beco V; Lettéron P; Robin MA; Moreau C; El Kahwaji J; Verthier N; Feldmann G; Fromenty B; Pessayre D
Gastroenterology; 1998 Apr; 114(4):764-74. PubMed ID: 9516397
[TBL] [Abstract][Full Text] [Related]
36. Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha.
Ramirez-Tortosa MC; Ramirez-Tortosa CL; Mesa MD; Granados S; Gil A; Quiles JL
Free Radic Biol Med; 2009 Oct; 47(7):924-31. PubMed ID: 19539747
[TBL] [Abstract][Full Text] [Related]
37. Drugs and steatohepatitis.
Farrell GC
Semin Liver Dis; 2002; 22(2):185-94. PubMed ID: 12016549
[TBL] [Abstract][Full Text] [Related]
38. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling.
Zeng X; Yang J; Hu O; Huang J; Ran L; Chen M; Zhang Y; Zhou X; Zhu J; Zhang Q; Yi L; Mi M
Antioxid Redox Signal; 2019 Jan; 30(2):163-183. PubMed ID: 29310441
[No Abstract] [Full Text] [Related]
39. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model.
Serviddio G; Bellanti F; Tamborra R; Rollo T; Romano AD; Giudetti AM; Capitanio N; Petrella A; Vendemiale G; Altomare E
Eur J Clin Invest; 2008 Apr; 38(4):245-52. PubMed ID: 18339004
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial oxidative injury: a key player in nonalcoholic fatty liver disease.
Dornas W; Schuppan D
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G400-G411. PubMed ID: 32597705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
